The suggestion that DPP inhibitors may increase cancer risk and increased S1P activity has been reported as a mediator of oncogenicity: highlighting the “ying and yang” of comorbidity treatments (reviewed in [15]). This evidence concerns the gene MBTPS1 and cancer.